• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用头孢他啶-阿维巴坦治疗急性淋巴细胞白血病继发于耐碳青霉烯肺炎克雷伯菌血流感染的播散性器官和组织感染:两例报告

Disseminated organ and tissue infection secondary to carbapenem-resistant Klebsiella pneumoniae bloodstream infection for acute lymphoblastic leukemia treated with ceftazidime-avibactam: Two case reports.

作者信息

He Mingxia, Jiang Yuxia, Wu Haiying, Xu Xiaofeng, Jiang Huifang

机构信息

Department of Hematology, Tongde Hospital of Zhejiang Province, Hangzhou, P.R. China.

Department of Hematology, Hangzhou Red Cross Hospital, Hangzhou, Zhejiang, P.R. China.

出版信息

Medicine (Baltimore). 2025 Jan 10;104(2):e41195. doi: 10.1097/MD.0000000000041195.

DOI:10.1097/MD.0000000000041195
PMID:39792772
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11730841/
Abstract

RATIONALE

Carbapenem-resistant Klebsiella pneumoniae (CRKP) bloodstream infections are a severe complication resulting from granulocyte deficiency following chemotherapy for hematologic malignancies and have a high mortality rate. However, reports of disseminated organ infections secondary to bloodstream infections are rare.

PATIENT CONCERNS AND DIAGNOSES

We report 2 cases of patients with acute lymphoblastic leukemia who both developed CRKP bloodstream infections during the granulocyte deficiency stage following chemotherapy, with 1 case of secondary bacterial liver abscess and 1 case of secondary septic arthritis.

INTERVENTIONS AND OUTCOMES

Based on the results of drug sensitivity testing, both patients were treated with ceftazidime-avibactam, and the infections were rapidly and effectively controlled without significant adverse effects.

LESSONS

Ceftazidime-avibactam exhibited satisfactory efficacy and safety in the 2 cases of disseminated organ infection secondary to CRKP bloodstream infection following chemotherapy for acute lymphoblastic leukemia.

摘要

理论依据

耐碳青霉烯类肺炎克雷伯菌(CRKP)血流感染是血液系统恶性肿瘤化疗后粒细胞缺乏引起的严重并发症,死亡率很高。然而,继发于血流感染的播散性器官感染报告很少。

患者情况与诊断

我们报告2例急性淋巴细胞白血病患者,均在化疗后的粒细胞缺乏阶段发生CRKP血流感染,其中1例继发细菌性肝脓肿,1例继发化脓性关节炎。

干预措施与结果

根据药敏试验结果,2例患者均接受头孢他啶-阿维巴坦治疗,感染迅速有效得到控制,且无明显不良反应。

经验教训

头孢他啶-阿维巴坦在2例急性淋巴细胞白血病化疗后CRKP血流感染继发播散性器官感染病例中显示出令人满意的疗效和安全性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80df/11730841/e3f488dfb4d3/medi-104-e41195-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80df/11730841/993a34fe6691/medi-104-e41195-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80df/11730841/e3f488dfb4d3/medi-104-e41195-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80df/11730841/993a34fe6691/medi-104-e41195-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80df/11730841/e3f488dfb4d3/medi-104-e41195-g002.jpg

相似文献

1
Disseminated organ and tissue infection secondary to carbapenem-resistant Klebsiella pneumoniae bloodstream infection for acute lymphoblastic leukemia treated with ceftazidime-avibactam: Two case reports.用头孢他啶-阿维巴坦治疗急性淋巴细胞白血病继发于耐碳青霉烯肺炎克雷伯菌血流感染的播散性器官和组织感染:两例报告
Medicine (Baltimore). 2025 Jan 10;104(2):e41195. doi: 10.1097/MD.0000000000041195.
2
Clinical outcomes of phenotype-guided treatment in group D carbapenemase-producing bacteremia.产D组碳青霉烯酶菌血症中表型导向治疗的临床结局
Microbiol Spectr. 2025 Jul;13(7):e0027325. doi: 10.1128/spectrum.00273-25. Epub 2025 May 27.
3
Efficacy and safety of ceftazidime-avibactam compared to other antimicrobials for the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae strains, a systematic review and meta-analysis.头孢他啶-阿维巴坦与其他抗菌药物治疗碳青霉烯类耐药肺炎克雷伯菌引起的感染的疗效和安全性:系统评价和荟萃分析。
Microb Pathog. 2023 Jun;179:106090. doi: 10.1016/j.micpath.2023.106090. Epub 2023 Mar 31.
4
Ceftazidime/avibactam for the treatment of bloodstream infection due to carbapenemase-producing Enterobacterales in onco-haematologic neutropenic patients (the TARZAN study).头孢他啶/阿维巴坦治疗肿瘤血液科中性粒细胞减少患者产碳青霉烯酶肠杆菌科细菌所致血流感染(TARZAN研究)
J Antimicrob Chemother. 2025 Jun 3;80(6):1673-1681. doi: 10.1093/jac/dkaf120.
5
Evolution of ceftazidime-avibactam resistance driven by variation in to during treatment of ST11-K64 hypervirulent .在ST11-K64高毒力肺炎克雷伯菌治疗期间,由blaKPC至blaNDM变异驱动的头孢他啶-阿维巴坦耐药性演变
Front Cell Infect Microbiol. 2025 Jun 6;15:1607127. doi: 10.3389/fcimb.2025.1607127. eCollection 2025.
6
A comparative analysis of clinical outcomes in hematological patients afflicted with bacteremia attributable to carbapenem-resistant versus .耐碳青霉烯类所致菌血症血液病患者临床结局的比较分析 与……相对比 (原文此处不完整)
Front Cell Infect Microbiol. 2025 Jun 17;15:1600746. doi: 10.3389/fcimb.2025.1600746. eCollection 2025.
7
A pre-post quasi-experimental study of antimicrobial stewardship exploring the impact of a multidisciplinary approach aimed at attaining an aggressive joint pharmacokinetic/pharmacodynamic target with ceftazidime/avibactam on treatment outcome of KPC-producing infections and on ceftazidime/avibactam resistance development.一项关于抗菌药物管理的前后对照准实验研究,探讨多学科方法的影响,该方法旨在通过头孢他啶/阿维巴坦实现积极的联合药代动力学/药效学目标,对产KPC感染的治疗结果以及头孢他啶/阿维巴坦耐药性发展的影响。
Antimicrob Agents Chemother. 2025 Jul 2;69(7):e0048825. doi: 10.1128/aac.00488-25. Epub 2025 Jun 6.
8
Ceftazidime-Avibactam resistance in clinical isolates of carbapenem-resistant Klebsiella pneumoniae: A phenotypic and genotypic analysis.碳青霉烯类耐药肺炎克雷伯菌临床分离株中头孢他啶-阿维巴坦耐药性:表型和基因型分析。
Indian J Med Microbiol. 2024 May-Jun;49:100603. doi: 10.1016/j.ijmmb.2024.100603. Epub 2024 May 7.
9
Multicenter evaluation of ceftazidime-avibactam use in carbapenem-resistant Klebsiella pneumoniae bloodstream infections in OXA-48 endemic regions.多中心评价在产碳青霉烯酶肺炎克雷伯菌血流感染(OXA-48 流行地区)中使用头孢他啶-阿维巴坦。
Sci Rep. 2024 Nov 1;14(1):26337. doi: 10.1038/s41598-024-77259-z.
10
Carbapenem-resistant Klebsiella pneumoniae outbreak with monoclonal spread: Evaluation of resistance genes and ceftazidime-avibactam susceptibility.单克隆传播的耐碳青霉烯肺炎克雷伯菌暴发:耐药基因及头孢他啶-阿维巴坦敏感性评估
Indian J Med Microbiol. 2023 Nov-Dec;46:100431. doi: 10.1016/j.ijmmb.2023.100431. Epub 2023 Jul 27.

本文引用的文献

1
Staphylococcus aureus Osteomyelitis: Bone, Bugs, and Surgery.金黄色葡萄球菌骨髓炎:骨、细菌和手术。
Infect Immun. 2020 Jun 22;88(7). doi: 10.1128/IAI.00932-19.
2
Emergence of ST11-K47 and ST11-K64 hypervirulent carbapenem-resistant in bacterial liver abscesses from China: a molecular, biological, and epidemiological study.中国细菌性肝脓肿中 ST11-K47 和 ST11-K64 超毒力耐碳青霉烯肠杆菌科细菌的出现:一项分子、生物学和流行病学研究。
Emerg Microbes Infect. 2020 Feb 9;9(1):320-331. doi: 10.1080/22221751.2020.1721334. eCollection 2020.
3
Evaluation of the efficacy and safety of ceftazidime/avibactam in the treatment of Gram-negative bacterial infections: a systematic review and meta-analysis.
评估头孢他啶/阿维巴坦治疗革兰氏阴性菌感染的疗效和安全性:系统评价和荟萃分析。
Int J Antimicrob Agents. 2018 Oct;52(4):443-450. doi: 10.1016/j.ijantimicag.2018.07.004. Epub 2018 Aug 31.
4
Ceftazidime/Avibactam for Refractory Bacteremia, Vertebral Diskitis/Osteomyelitis with Pre-Vertebral Abscess and Bilateral Psoas Pyomyositis Secondary to Klebsiella Pneumoniae Carbapenemase-Producing Bacteria (KPC).头孢他啶/阿维巴坦用于治疗由产肺炎克雷伯菌碳青霉烯酶(KPC)的细菌引起的难治性菌血症、伴有椎前脓肿的椎间盘炎/骨髓炎以及双侧腰大肌脓性肌炎。
P R Health Sci J. 2018 Jun;37(2):128-131.
5
Efficacy and safety of ceftazidime/avibactam: a systematic review and meta-analysis.头孢他啶/阿维巴坦的疗效和安全性:系统评价和荟萃分析。
J Antimicrob Chemother. 2018 Aug 1;73(8):2021-2029. doi: 10.1093/jac/dky124.
6
Lumbar arthrodesis infection by multi-resistant Klebsiella pneumoniae, successfully treated with implant retention and ceftazidime/avibactam.腰椎融合术感染多重耐药肺炎克雷伯菌,通过保留植入物和使用头孢他啶/阿维巴坦成功治疗。
Rev Esp Cir Ortop Traumatol (Engl Ed). 2018 Nov-Dec;62(6):471-473. doi: 10.1016/j.recot.2018.02.002. Epub 2018 Apr 7.
7
Carbapenem-resistant Klebsiella pneumoniae vertebral osteomyelitis in a renal transplant recipient treated with ceftazidime-avibactam.接受头孢他啶-阿维巴坦治疗的肾移植受者发生耐碳青霉烯类肺炎克雷伯菌性脊椎骨髓炎
Transpl Infect Dis. 2018 Apr;20(2):e12837. doi: 10.1111/tid.12837. Epub 2018 Feb 19.
8
Next-generation sequencing technologies and their application to the study and control of bacterial infections.下一代测序技术及其在细菌感染研究和控制中的应用。
Clin Microbiol Infect. 2018 Apr;24(4):335-341. doi: 10.1016/j.cmi.2017.10.013. Epub 2017 Oct 23.
9
A Systematic Review and Meta-analyses of the Clinical Epidemiology of Carbapenem-Resistant Enterobacteriaceae.碳青霉烯类耐药肠杆菌科的临床流行病学系统评价和荟萃分析。
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01730-17. Print 2018 Jan.
10
Carbapenem-resistant Enterobacteriaceae in special populations: Solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies.特殊人群中的耐碳青霉烯肠杆菌科:实体器官移植受者、造血干细胞移植受者和血液恶性肿瘤患者。
Virulence. 2017 May 19;8(4):391-402. doi: 10.1080/21505594.2016.1213472. Epub 2016 Jul 28.